Zhang H, Lu B. microRNAs as biomarkers of ovarian cancer. Expert Rev Anticancer Ther. 2020;20:373–85.

Article  CAS  PubMed  Google Scholar 

Dion L, Carton I, Jaillard S, Nyangoh Timoh K, Henno S, Sardain H, et al. The landscape and therapeutic implications of molecular profiles in epithelial ovarian cancer. J Clin Med. 2020;9:2239.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu L, Liu P, Liang Z, Li R, Shen M, Xu H, et al. Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer. Anticancer Drugs. 2019;30:554–61.

Article  CAS  PubMed  Google Scholar 

Lee A. Fuzuloparib: first approval. Drugs. 2021;81:1221–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamashita T. [Treatment of delusions of parasitosis: efficacy of transcutaneous electrical stimulation]. Seishin Shinkeigaku Zasshi. 1986;88:1–13.

CAS  PubMed  Google Scholar 

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–7.

Article  CAS  PubMed  Google Scholar 

Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852–61.

Article  CAS  PubMed  Google Scholar 

Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: clinical utility and possibilities of overcoming resistance. Gynecol Oncol. 2017;147:695–704.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chow JT, Salmena L. Recent advances in PTEN signalling axes in cancer. Fac Rev. 2020;9:31.

Article  PubMed  PubMed Central  Google Scholar 

Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128:157–70.

Article  CAS  PubMed  Google Scholar 

Planchon SM, Waite KA, Eng C. The nuclear affairs of PTEN. J Cell Sci. 2008;121:249–53.

Article  CAS  PubMed  Google Scholar 

Ming M, He YY. PTEN in DNA damage repair. Cancer Lett. 2012;319:125–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1:315–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N, Bachoo RM, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 2010;70:5457–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med. 2010;2:53ra75.

Article  PubMed  Google Scholar 

Hopkins BD, Hodakoski C, Barrows D, Mense SM, Parsons RE. PTEN function: the long and the short of it. Trends Biochem Sci. 2014;39:183–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science. 1998;280:1614–7.

Article  CAS  PubMed  Google Scholar 

Liu H, Lu Z, Shi X, Liu L, Zhang P, Golemis EA, et al. HSP90 inhibition downregulates DNA replication and repair genes via E2F1 repression. J Biol Chem. 2021;297:100996.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Z, Shang D, Qiu L, Guo C, Li Y, Liu H, et al. 4,5-Diphenyl-2-methyl picolinate induces cellular senescence by accumulating DNA damage and activating associated signaling pathways in gastric cancer. Life Sci. 2019;238:116973.

Article  CAS  PubMed  Google Scholar 

Chen S, Gu T, Lu Z, Qiu L, Xiao G, Zhu X, et al. Roles of MYC-targeting long non-coding RNA MINCR in cell cycle regulation and apoptosis in non-small cell lung Cancer. Respir Res. 2019;20:202.

Article  PubMed  PubMed Central  Google Scholar 

Shang DS, Zhou TC, Zhuang XY, Wu YF, Liu HQ, Tu ZG. Molecular dissection on inhibition of Ras-induced cellular senescence by small t antigen of SV40. Cell Mol Life Sci. 2022;79:242.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lanczky A, Gyorffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res. 2021;23:e27633.

Article  PubMed  PubMed Central  Google Scholar 

Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tu Z, Aird KM, Bitler BG, Nicodemus JP, Beeharry N, Xia B, et al. Oncogenic Ras regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence. Dev Cell. 2011;21:1077–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu Z, Yuan S, Ruan L, Tu Z, Liu H. Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial-mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer. Cell Death Dis. 2022;13:304.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer. 2016;60:49–58.

Article  CAS  PubMed  Google Scholar 

Boussios S, Karihtala P, Moschetta M, Karathanasi A, Sadauskaite A, Rassy E, et al. Combined strategies with poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: a literature review. Diagnostics. 2019;9:87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arora S, Balasubramaniam S, Zhang H, Berman T, Narayan P, Suzman D, et al. FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer. Oncologist. 2021;26:e164–72.

Article  CAS  PubMed